Press Releases July 20, 2026 06:00 AM

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Seer's Special Committee unanimously rejects CEO's unsolicited acquisition proposal, citing undervaluation and long-term growth potential.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SEER

Seer, Inc.'s Special Committee of independent directors thoroughly reviewed an unsolicited acquisition proposal from the company's CEO Omid Farokhzad, M.D. to acquire all Class A shares at $2.45 per share plus contingent value rights. The Committee unanimously rejected the proposal, determining it undervalues Seer and does not fully recognize the company's long-term growth prospects and technology potential. The decision reflects fiduciary responsibility to protect shareholder interests and confidence in the company's future growth.

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
SEER
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The Special Committee, composed of independent directors, unanimously rejected the CEO's unsolicited acquisition offer as undervaluing the company.
  • The proposal included contingent value rights intended to benefit shareholders from future technological developments, but these were judged insufficient by the Committee.
  • Seer emphasizes its position as a pioneer in unbiased proteomic technologies with significant growth potential, which the Committee believes is not reflected in the offer.
  • Sectors impacted include biotechnology, proteomics, healthcare technology, and investor relations for growth-oriented biotechs.

REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of Directors, consisting of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has thoroughly reviewed and unanimously rejected the unsolicited, non-binding proposal received on July 1, 2026, from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the “Proposal”).

Consistent with its fiduciary duties, the Special Committee carefully reviewed the Proposal in consultation with its independent advisors and unanimously determined that it is not in the best interests of Seer’s stockholders because it undervalues Seer and fails to reflect the value of Seer’s long-term growth prospects. In reaching this conclusion, the Special Committee noted that the contingent value rights included in the Proposal, which are intended to allow Seer’s stockholders to benefit from future developments related to Seer’s technology, were insufficient to fully value Seer and its growth potential.

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at [email protected].

Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s prospects, growth potential and technology. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
[email protected]

Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449

Investor Contact:
Marissa Bych
[email protected]


Risks

  • The uncertainty surrounding acquisition proposals could impact shareholder sentiment and stock price volatility in the near term.
  • Forward-looking statements highlight risks related to future financial performance, growth prospects, and technological development inherent to the biotech sector.
  • Potential conflicts of interest since the proposal originated from Seer's CEO, which may lead to governance scrutiny and market perception challenges.

More from Press Releases

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress Jul 20, 2026 Columbia Financial, Inc. Announces Completion of Second Step Conversion and $1.7 Billion Stock Offering and Acquisition of Northfield Bancorp, Inc. Jul 20, 2026 Quantum BioPharma Announces Intention to Settle Debt Jul 20, 2026 AMR Resources Acquisition Corp Announces Closing of $260,000,000 Initial Public Offering, Including Partial Exercise of Underwriters’ Over-Allotment Option Jul 20, 2026 Century Aluminum Applauds President Trump’s Action to Spur Domestic Aluminum Production Jul 20, 2026